Get started
MESOBLAST LIMITEDMESOBLAST LIMITEDMESOBLAST LIMITED

MESOBLAST LIMITED

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals

MSB trade ideas

Finer Market Points: ASX Top 10 Momentum Stocks: 4 Apr 2024ASX:MSB AMEX:GLV AMEX:MAG NYSE:MMC NYSE:MMI NYSE:FND NYSE:TPC NASDAQ:PAA NYSE:PNR AMEX:USL Momentum leading shares are the market's best performers today. They are the fastest-growing shares on the ASX over the last 90 days. These companies can't get to be leaders without first appearing on our Launch Pad list. The Launch Pad List is published weekly on Fridays. Today's ASX's Top 10 Quarterly Momentum Stocks are: Mesoblast Limited (MSB) Global Oil & Gas Limited (GLV) Magmatic Resources Limited (MAG) Mitre Mining Corporation Limited (MMC) Metro Mining Limited (MMI) Findi Limited (FND) TPC Consolidated Limited (TPC) Pharmaust Limited (PAA) Pantoro Limited (PNR) Unico Silver Limited (USL)
ASX:MSB
by ch886
MSB squeezes stubborn longs to their death.. Off topic but as an leading indicator for "market timing" is when defensive stocks return to their original strongest demand zones from their origins of a past move & are met again for another strong rally, this seems it could to be happening to MBS, time will tell! With that said overall markets could be nearing their record highs and potentially pullback or reversal may be closest over coming months or so.. well technical analysis anyway... if so.. and that's true MSB could return to bullish status for me, if, and when PA is clear throughout my t/f's. Good discount levels are near yes !! but only if price action tells me so. still no trade since last post .. and if no PA, price can keep dropping and without me. Market sentiment :Remember worlds dumping this atm... with new ll today and an interesting monthly close bar! and timing of the news announcement. all the while to the informed trader price structure looks somewhat positive upon it slow entry, returning to back to monthly demand zone and region. Are our big boys waiting here?!!?!? not sure.. whats interesting is the Timing with Afghan crisis unfolding.. sad, but MONEY rules the world! Theres no clear PA to confirm buyers are here yet or even active here... an entry long here would be pure gambling on my behalf. I'll wait for on my LTF top down analysis , patience is now my friend.. stay safe out there!! Perma
ASX:MSB
by Permaculture
1
Reduction in Heart Attacks, Strokes and Cardiac DeathSingle Dose of Rexlemestrocel-L Provides Substantial and Durable Reduction in Heart Attacks, Strokes and Cardiac Death in Patients With Chronic Heart Failure results from the landmark DREAM-HF randomized controlled Phase 3 trial in 537 treated patients with chronic heart failure with reduced left ventricular ejection fraction (HFrEF) who received rexlemestrocel-L (REVASCOR®) or control sham. A single dose of rexlemestrocel-L resulted in substantial and durable reductions in heart attacks, strokes, and cardiac deaths. The incidence of heart attacks and strokes were reduced by 60% over a median follow-up period of 30 months following a single dose of rexlemestrocel-L in the population of 537 patients with New York Heart Association (NYHA) class II or III chronic heart failure (5% vs 13%, p=0.002). The incidence of death from cardiovascular causes was reduced by 60% following a single dose of rexlemestrocel-L in the 206 patients with NYHA class II disease (8% vs 20%, p=0.037) finance.yahoo.com
NASDAQ:MESO
by AlenCiken
1
MSB - Bullish (A Medium to Long Term Buying Opportunity)1. Price has plummeted down and stopped at exact upward sloping 50 Months Moving Average 2. Price got support exactly on the 200 Weeks Moving Average 3. Price got support at a very strong Monthly Support Level I believe this is a great medium to long term buying buying opportunity, as price got supported at many confluence levels, as this might be a Higher Low on the Monthly and the Weekly Chart. The support level of $2.00 is very strong. As price got dumped aggressively, I believe it will take some time for it to move up very quickly. I think price will consolidate and coil and there will be a lot of accumulation which may take time for price to take off. I will be watching price action and will enter once bullish price action is confirmed. Please note these are my own notes, by no means trading advice. Please do your own research before entering into any trade.
ASX:MSBLong
by AsimMirzaTrader
3
MSB - Updated AnalysisI hope you find my analysis useful. From what I can see, price seems to be holding within the trend channel (bullish sign) The moving averages are beginning to cross, and as you can see in the past, when that occurred, price rose (bullish sign). Price needs to hold above the lower trend channel and break past the .786 fib to confirm bullish price action. Stock is very news sensitive, price may rise in anticipation of an announcement and come crashing down if the announcement is lackluster. Trade with caution, but from what I'm seeing, right now is a good time to either average in or enter the trade for a decent risk-vs-reward scenario. *Not financial advice* *Just my opinion* *All investing and trading involves risk*
ASX:MSBLong
by TheTraderAndy
MESO, Triangle Descending (bearish)I found this pattern at tickeron website with the following data: STATUS = Confirmed CURRENT CONFIDENCE = 71% TARGET (EXIT) PRICE = 11.21 USD BREAKOUT (ENTRY) PRICE = 11.94 USD DISTANCE TO TARGET PRICE = 6.57% EMERGED ON = Oct 12, 08:00 AM (EDT) CONFIRMED ON = Oct 12, 11:59 AM (EDT) WITH CONFIDENCE LEVEL = 85% The Descending Triangle pattern has a horizontal bottom (1, 3, 5) which represents the support level, and a down­-sloping top line (2, 4). The breakout can be either up or down and the direction of the breakout determines which corresponding price level is the target. This pattern is commonly associated with directionless markets since the contraction (narrowing) of the market range signals that neither bulls nor bears are in control. When the price of a security consolidates in a somewhat volatile fashion, it may indicate growing investor concern that the price is set to break out. Trade idea If the price breaks out from the bottom pattern boundary, day traders and swing traders should trade with the DOWN trend. Consider selling the security short or buying a put option at the downward breakout price level. To identify an exit, compute the target price, by subtracting the pattern height from the breakout point. For downward breakouts the breakout level is the bottom horizontal line (1, 3, 5). Pattern height is the difference between the level of the bottom horizontal line and the highest high. To limit potential loss when price suddenly goes in the wrong direction, consider placing a stop order to buy back a short position or sell a put option at or above the breakout price.
NASDAQ:MESOShort
by AlTorress
MSB - Technical Analysis - 100%+ gains?I hope you like my analysis. Very risky stock to invest in, but with potentially big upside in the scenario that there is good news from the FDA in future, which could conclude with a 3-4month Phase 4 trial (CRL) and see the price action head towards 8.60$, after breaking through previous resistances and fib-levels on the way ... this is in order to respect the current trendline which formed (weak trend, given the large gap in the chart) since close Friday/open today. My conservative analysis based on 2 fundamental outcomes would be the following: From now til around March next year, if there are mostly low-impact news/announcements along the way, and no serious negative ones (impossible to predict), the stock will likely trend up from here, riding hype of a potentially large and favorable outcome from the FDA, as well as other potential catalysts. I estimate based off my TA as well as FA that it may take up until Feb 21' to reach the previous high (5.70) - 0 on the fib. I estimate if that happens + good news comes out, 8.60 is not unreasonable of a target. Higher in future if they release positive outcomes for their other drugs in trials, if they are able to expand their applications for drugs in the pipeline, and nail distribution. This will lead to more profits, cash flow, and hopefully no debt on their balance sheet. If FDA doesn't approve, then I am convinced the FDA is corrupt, only cares about national interests, or who bribes them the most. You have Opioids/fentanyl crisis in America because they're prescribed like candy, and where opioids are the most commonly prescribed for lower back pain -- another ailment MSB's product line can potentially treat. RSI is currently oversold, based on the space between observable "cycles" in this stock, there's usually around 120-130 days between bull/bear trends (based off most recent 3). 120-130 days matches my thesis of march/april if all goes well. It could happen much sooner, much later, or not at all. But I think probability leans in favor of this outcome. Of course, nobody has a crystal ball. *NOT FINANCIAL ADVICE, DYOR. ALL INVESTING CARRIES RISK OF LOSS OF CAPITAL. ONLY INVEST WHAT YOU CAN AFFORD TO LOSE. *
ASX:MSBLong
by TheTraderAndy
4
MESOBLAST (MSB) - FDA will likely approve Ryoncil (analysis)MSB is developing Ryoncil - an IV stem cell therapy for the treatment of acute graft versus host disease (aGVHD) in paediatrics. aGCHD is a potentially life threatening (up to 70-90% mortality) complication of bone marrow transplants (indicated for leukemia/lymphoma etc). Ryoncil has been accepted by the FDA for priority review with a PDUFA action date of US 30th September (1st Oct in AUS). Why might the FDA approve Ryoncil? Probability wise: - Oncology therapy's have an average 88% probability of being approved once they have been accepted for review (data averaged from results from Wong et al (2018), Thomas et al (2016), Hay et al (2014), and DiMasi et al (2010)). - As part of the review, the FDA requested a recommendation from the Oncologist Drugs Advisory Committee (clinical oncology academics and statisticians) who on Aug 13th voted 9:1 that the available data supports the efficacy of Ryoncil. - Ryoncil has been approved in Japan for the last 5 years with strong yoy growth. Benefit-risk ethics analysis: - There are no FDA approved treatments for aGCHD in pediatrics and no therapies are considered standard of care. - Ryoncil is effective vs placebo (28d survival 64% vs 38%, 100d survival 79% vs 54%). - Adverse Effects of Ryoncil were not statistically different from placebo. In fact unapproved treatments (steroids) carry high risk of toxicity. - aGCHD has a 70-90% mortality rate, there are no FDA approved treatments, Ryoncil appears to be effective, risk of doing harm by approving Ryoncil is low. It seems like the ethical decision is to approve Ryoncil. Why might not the FDA approve Ryoncil? - The FDA prefers double-blinded, placebo-controlled RCT's to show effectiveness. However, due to the high mortality rate of aGCHD, enrolling children into an RCT is clearly not ethical. I'd argue that the single arm study comparing to an external control population is as good as you're gonna get. It also does not need to be blinded as the primary endpoint is mortality. The 9:1 ODAC vote seems to support this. - The study was small (N=14, N=13). It might be reasonable for the FDA to ask for another (potentially larger) study to replicate the results which is a risk. - Quality control concerns. The FDA raised concerns that the way MSB measure the potency of the Ryoncil (CQA's) may not be enough to ensure the clinical effectiveness of the product. I'm no expert in this part but when MSB responded to these concerns in the webcast, they kind of just reiterated the CQA's from their manufacturing were very high but didn't really address the concern that the CQA's might not translate to clinical effectiveness. It might be reasonable for the FDA to ask for more data on this. - Even if more data is requested, Ryoncil can still be provisionally approved. Conclusion: The FDA will likely approve or provisionally approve (with the request of more data) Ryoncil therapy for pediatric aGVHD in the US which will strongly improve the revenue potential of MSB.
ASX:MSBLong
by Sean_Kenworthy
MSB – MESOBLAST LIMITED Targeting $5.35Hello Fellow Traders! The XJO (ASX200) has sold off from the peak made on August 25th following the SPX(US500) and Nasdaq during uncertain global times and Covid numbers starting to increase again in Europe. While the XJO continued to fall in the past 5 trading days, MSB has experienced supreme buying pressure continuing to retest $5.00. MSB is a Bio – Pharmaceutical company that offers products in the area of cardiovascular, spine orthopedic disorders, oncology, hematology, and immune-mediated and inflammatory diseases. Key Points: - Price holding above the 200 EMA - Price holding above the 50 EMA - Bullish wedge pattern below range break out - Fibonacci 61.8% level providing support at $5.00 - Volume increasing showcasing buyers’ momentum - RSI also breaking trendline - Superior risk to reward - SPX and NAS100 both in the green overnight Key Levels: Support - 5.00, 50 EMA, 200 EMA Resistance – 5.25, 5.35 Entry Zone: Optimal entry provides the greatest reward to risk ratio while supporting entry is a zone for reversal signals. Optimal Entry – 5.05 Supporting Entry – 5.10 Candle Reversals for entry - Bullish Hammer - Bullish Engulfing - Bullish Piercing The Risk: As traders, it is your job to mitigate the risk and only trade structures that provide high probability and great reward to risk ratios. If you are not comfortable with defined exit levels, experiment with Moving Averages to help set solid exit rules to protect your capital. IF: Price breaks below 5.00 and violates 50 EMA– this would suggest the structure is not in our favour and would be wise to reduce exposure or close the trade until a solid signal gives us reasons to re-enter. Reward / Reward Targets: Optimal Entry $5.05 – Target 1 $5.25 = 3.3x Reward to Risk Optimal Entry $5.05 – Target 2 $5.35 = 5x Reward to Risk Supporting Entry 5.10 – Target 1 $5.25 = 1.6x Reward to Risk Supporting Entry 5.10 – Target 2 $5.35 = 2.6x Reward to Risk
ASX:MSBLong
by tradetheday
$MSB:ASX - MESOBLAST LIMITED - Up 150% over 12 monthsMesoblast has had a strong run especially over the last couple of months. Has had a bit of a pullback off its highs so could be well worth a watch to see if it continues back on its upward march. I've set an alert at $3.05 to see what happens. Mesoblast Ltd. is a biopharmaceutical company, which engages in the research, development, and market of mesenchymal lineage adult stem cell technology platform. Its medicines target the cardiovascular diseases, spine orthopedic disorders, oncology and hematology, immune-mediated, and inflammatory diseases. The company was founded by Itescu Silviu on June 8, 2004 and is headquartered in Melbourne, Australia.
ASX:MSBLong
by zAngus